The EGF receptor family: spearheading a merger of signaling and therapeutics

• Published in: Current opinion in cell biology Vol. 19; no. 2; pp. 124 - 134
• Main Authors: Bublil, Erez M, Yarden, Yosef
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2007
• Subjects: Allosteric Regulation; Animals; Computer Simulation; Humans; Internal Medicine; Ligands; Models, Biological; Models, Molecular; Neoplasms - drug therapy; Neoplasms - metabolism; Neuregulins - metabolism; Protein Conformation; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, Epidermal Growth Factor - chemistry; Receptor, Epidermal Growth Factor - metabolism; Signal Transduction
• ISSN: 0955-0674; 1879-0410
• DOI: 10.1016/j.ceb.2007.02.008

The ErbB receptor tyrosine kinases evolved as key regulatory entities enabling the extracellular milieu to communicate with the intracellular machinery to bring forth the appropriate biological response in an ever-changing environment. Since its discovery, many aspects of the ErbB family have been deciphered, with emphasis on aberration of signaling in human diseases. However, only now, with the availability of the atomic coordinates of these receptors, can we construct a comprehensive model of the mechanisms underlying ligand-induced receptor dimerization and subsequent tyrosine kinase activation. Furthermore, the recent introduction of new high-throughput screening methodologies, combined with the materialization of a systems biology perspective, reveals an overwhelming network complexity, enabling robust signaling and evolvability. This knowledge is likely to impact our view of diseases as system perturbations and resistance to ErbB-targeted therapeutics as manifestations of robustness.